Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $47
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $50 to $47.
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $50 to $47.